GlaxoSmithKline (GSK) has reached an exclusive worldwide options and license agreement for a promising smoking cessation vaccine from Nabi Pharmaceuticals for more than US$500 M. It is brave move by GSK in light of other nicotine vaccines not living up to expectations in clinical trials.